Breast Cancer Registry Platform
Recruiting
- Conditions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 5000
- Registration Number
- NCT03417115
- Locations
- 🇩🇪
Multiple sites all over germany, Multiple Locations, Germany
Registry Platform Urologic Cancer
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 1750
- Registration Number
- NCT03374267
- Locations
- 🇩🇪
Multiple sites, Germany, Multiple Locations, Germany
Myeloma Registry Platform (MYRIAM)
Recruiting
- Conditions
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 2200
- Registration Number
- NCT03308474
- Locations
- 🇩🇪
Multiple sites all over germany, Multiple Locations, Germany
Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 647
- Registration Number
- NCT03043950
- Locations
- 🇩🇪
Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Baden-Württemberg, Germany
Patient Reported Outcomes Registry in Patient With Cancer Cachexia
Completed
- Conditions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 253
- Registration Number
- NCT02983500
- Locations
- 🇩🇪
Multiple sites all over Germany, Multiple Locations, Germany
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 359
- Registration Number
- NCT02970747
- Locations
- 🇩🇪
Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 388
- Registration Number
- NCT02894398
- Locations
- 🇩🇪
Research Site, Wilhelmshaven, Germany
Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC
Completed
- Conditions
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 408
- Registration Number
- NCT02799862
- Locations
- 🇩🇪
iOMEDICO, Freiburg, Baden-Württemberg, Germany
Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma
Completed
- Conditions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2021-03-25
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 98
- Registration Number
- NCT02537743
- Locations
- 🇩🇪
Multiple sites all over Germany, Multiple Locations, Germany
Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma
Completed
- Conditions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 172
- Registration Number
- NCT02537808
- Locations
- 🇩🇪
Hämatologisch-Onkologische Schwerpunktpraxis, Bochum, Germany
© Copyright 2024. All Rights Reserved by MedPath